Michael Neely
Overview
Explore the profile of Michael Neely including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
1324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Segers H, Deville J, Muller W, Manzanares A, Desai A, Neely M, et al.
Antimicrob Agents Chemother
. 2024 Nov;
68(12):e0048424.
PMID: 39540734
Invasive aspergillosis (IA) and mucormycosis (IM) cause significant morbidity and mortality in immunocompromised and/or hospitalized patients. Isavuconazonium sulfate, a prodrug of the antifungal triazole isavuconazole, has been approved for treatment...
2.
Avedissian S, Malik J, Podany A, Neely M, Rhodes N, Scarsi K, et al.
Sci Rep
. 2024 May;
14(1):10709.
PMID: 38729980
Three years after SARS-CoV-2 emerged as a global infectious threat, the virus has become endemic. The neurological complications such as depression, anxiety, and other CNS complications after COVID-19 disease are...
3.
Venugopalan V, Maranchick N, Hanai D, Hernandez Y, Joseph Y, Gore A, et al.
JAC Antimicrob Resist
. 2024 Jan;
6(1):dlad157.
PMID: 38259903
Objectives: Acute kidney injury (AKI) is a well-documented adverse effect observed with piperacillin/tazobactam in combination with vancomycin. The pharmacokinetics of these antibiotics when given in combination have not been previously...
4.
Bonate P, Barrett J, Ait-Oudhia S, Brundage R, Corrigan B, Duffull S, et al.
J Pharmacokinet Pharmacodyn
. 2023 Sep;
51(1):89.
PMID: 37670078
No abstract available.
5.
Bonate P, Barrett J, Ait-Oudhia S, Brundage R, Corrigan B, Duffull S, et al.
J Pharmacokinet Pharmacodyn
. 2023 Aug;
51(1):5-31.
PMID: 37573528
The current demand for pharmacometricians outmatches the supply provided by academic institutions and considerable investments are made to develop the competencies of these scientists on-the-job. Even with the observed increase...
6.
Sferra T, Merta T, Neely M, de Oliveira C, Lassaletta A, Fortuny Guasch C, et al.
J Pediatric Infect Dis Soc
. 2023 Jun;
12(6):334-341.
PMID: 37389891
Background: Therapies to prevent recurrence of Clostridioides difficile infection (CDI) in pediatric patients are needed. Bezlotoxumab is a fully human monoclonal antibody approved for prevention of recurrent CDI in adults....
7.
Orgel E, Knight K, Chi Y, Malvar J, Rushing T, Mena V, et al.
Clin Cancer Res
. 2023 May;
29(13):2410-2418.
PMID: 37134194
Purpose: Cisplatin-induced hearing loss (CIHL) is common and permanent. As compared with earlier otoprotectants, we hypothesized N-acetylcysteine (NAC) offers potential for stronger otoprotection through stimulation of glutathione (GSH) production. This...
8.
Malhotra S, Dasgupta-Tsinikas S, Yumul J, Kaneta K, Lenz A, Kizzee R, et al.
J Pediatr
. 2023 Apr;
259:113419.
PMID: 37044372
Objectives: To evaluate implementation of rifamycin-based regimens (RBR) for pediatric tuberculosis infection (TBI) treatment among 3 provider settings in a high-incidence county. Study Design: A multicenter, retrospective observational study was...
9.
Darlow C, Mcentee L, Johnson A, Farrington N, Unsworth J, Jimenez-Valverde A, et al.
J Antimicrob Chemother
. 2022 Sep;
77(12):3349-3357.
PMID: 36177766
Background: Annual mortality from neonatal sepsis is an estimated 430 000-680 000 infants globally, most of which occur in low- and middle-income countries (LMICs). The WHO currently recommends a narrow-spectrum...
10.
Yamada W, Kim S, Almoslem M, Kim S, Myrick J, Nole J, et al.
Antimicrob Agents Chemother
. 2022 Sep;
66(10):e0069522.
PMID: 36165631
Mycobacterium tuberculosis (Mtb) exists in various metabolic states, including a nonreplicating persister (NRP) phenotype which may affect response to therapy. We have adopted a model-informed strategy to accelerate discovery of...